PRECIOUS Study recruiting in the US
helping to deliver
The right treatment, to the right patient, at the right time.
PredictImmune is a global biotechnology company. Our technology is the result of over 15 years’ research at the University of Cambridge and guides personalised treatment of patients with immune-mediated diseases.
We are developing tools to enable better disease management and an improved quality of life for patients with chronic diseases including inflammatory bowel disease (IBD) and multiple sclerosis (MS). Our first product – PredictSURE® IBD – a prognostic test for both Crohn’s disease (CD) and ulcerative colitis (UC) is now available.
Latest news, blog & events
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE® IBD
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE® IBDCambridge, UK, 02 February: PredictImmune,...
The PRECIOUS Study – an update on PredictImmune’s observational study to demonstrate effectiveness of PredictSURE IBD in IBD patients in North America
In our most recent blog, we provide an update on the progress of the PRECIOUS study, discuss overcoming the challenges of recruiting to the study over the last few years and invite you to get involved and support the completion of the study…
PredictImmune presenting at the Crohn’s & Colitis Congress® 2023Cambridge, UK, 16th January 2023 PredictImmune are pleased to announce that they...